Comma Bio

About Comma Bio

Founded in 2006, Comma Bio (Biocomma) is a manufacturer of life science consumables, focusing on filtration, sample preparation, and life science products. The company has established a technology and industrialization platform centered on polymer filtration materials, adsorption and separation materials, and diagnostic membrane materials.

Biocomma's product portfolio includes consumables for various stages of laboratory work such as sample collection, transfer, filtration, separation, purification, preservation, and culture. Key product categories are pipette tip filters, solid-phase extraction (SPE), nucleic acid extraction kits, and gene synthesis tools. The company serves a global client base across more than 50 countries in scientific research, analytical testing, drug discovery, in-vitro diagnostics, and medical care. Its business model includes direct sales and OEM services, with facilities that are ISO 9001 and ISO 13485 certified.

The company was established to industrialize polymer filtration material technology and initially entered the sample filtration market. In 2021, Biocomma secured $15.6 million in a Series A venture funding round from investors including SB China Venture Capital, Shenzhen Capital Group, Shenzhen Gaoxin Investment, and YuanBio Venture Capital.